Histone deacetylase inhibitors in multiple myeloma

Main Article Content

Sarah Deleu
Eline Menu
Els Van Valckenborgh
Ben Van Camp
Joanna Fraczek
Isabelle Vande Broek
Vera Rogiers
Karin Vanderkerken *
(*) Corresponding Author:
Karin Vanderkerken | kvdkerke@vub.ac.be

Abstract

Novel drugs such as bortezomib and high dose chemotherapy combined with stem cell transplantation improved the outcome of multiple myeloma patients in the past decade. However, multiple myeloma often remains incurable due to the development of drug resistance governed by the bone marrow micro-environment. Therefore targeting new pathways to overcome this resistance is needed. Histone deacetylase (HDAC) inhibitors represent a new class of anti-myeloma agents. Inhibiting HDACs results in histone hyperacetylation and alterations in chromatine structure, which, in turn, cause growth arrest differentiation and/or apoptosis in several tumor cells. Here we summarize the molecular actions of HDACi as a single agent or in combination with other drugs in different in vitro and in vivo myeloma models and in (pre)clinical trials.

Downloads month by month

Downloads

Download data is not yet available.

Article Details

Author Biographies

Sarah Deleu

PhD student

Myeloma Research Center-Brussels, Department Hematology and Immunology, Free University Brussels (VUB), Brussels, Belgium

Eline Menu

Myeloma Research Center-Brussels, Department Hematology and Immunology, Free University Brussels (VUB), Brussels, Belgium

Els Van Valckenborgh

Dr.

Myeloma Research Center-Brussels, Department Hematology and Immunology, Free University Brussels (VUB), Brussels, Belgium

Ben Van Camp

Dr.

Myeloma Research Center-Brussels, Department Hematology and Immunology, Free University Brussels (VUB), Brussels, Belgium

Joanna Fraczek

PhD student

Department of Toxicology, Free University Brussels (VUB), Brussels, Belgium

Isabelle Vande Broek

Dr.

Myeloma Research Center-Brussels, Department Hematology and Immunology, Free University Brussels (VUB), Brussels, Belgium

Vera Rogiers

Prof.

Department of Toxicology, Free University Brussels (VUB), Brussels, Belgium

Karin Vanderkerken

Prof.

Myeloma Research Center-Brussels, Department Hematology and Immunology, Free University Brussels (VUB), Brussels, Belgium